JP2023522156A - コロナウイルスワクチン - Google Patents

コロナウイルスワクチン Download PDF

Info

Publication number
JP2023522156A
JP2023522156A JP2022560285A JP2022560285A JP2023522156A JP 2023522156 A JP2023522156 A JP 2023522156A JP 2022560285 A JP2022560285 A JP 2022560285A JP 2022560285 A JP2022560285 A JP 2022560285A JP 2023522156 A JP2023522156 A JP 2023522156A
Authority
JP
Japan
Prior art keywords
amino acid
seq
polypeptide
acid sequence
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522156A5 (https=
Inventor
ジョナサン ルーク ヒーニー，
スネハ ビシュワナス，
ジョージ カーネル，
デイビッド ウェルズ，
マッテオ フェラーリ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chancellor masters And Scholars Of University Of Cambridge
Original Assignee
Chancellor masters And Scholars Of University Of Cambridge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004826.0A external-priority patent/GB202004826D0/en
Priority claimed from GBGB2010672.0A external-priority patent/GB202010672D0/en
Priority claimed from GBGB2015775.6A external-priority patent/GB202015775D0/en
Priority claimed from GBGB2101824.7A external-priority patent/GB202101824D0/en
Priority claimed from GBGB2103214.9A external-priority patent/GB202103214D0/en
Application filed by Chancellor masters And Scholars Of University Of Cambridge filed Critical Chancellor masters And Scholars Of University Of Cambridge
Publication of JP2023522156A publication Critical patent/JP2023522156A/ja
Publication of JP2023522156A5 publication Critical patent/JP2023522156A5/ja
Priority to JP2025162640A priority Critical patent/JP2025184979A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022560285A 2020-04-01 2021-04-01 コロナウイルスワクチン Pending JP2023522156A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025162640A JP2025184979A (ja) 2020-04-01 2025-09-29 コロナウイルスワクチン

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB2004826.0 2020-04-01
GBGB2004826.0A GB202004826D0 (en) 2020-04-01 2020-04-01 Coronavirus vaccines
GBGB2010672.0A GB202010672D0 (en) 2020-07-10 2020-07-10 Coronovirus vaccines
GB2010672.0 2020-07-10
GBGB2015775.6A GB202015775D0 (en) 2020-10-05 2020-10-05 Coronavirus vaccines
GB2015775.6 2020-10-05
GB2101824.7 2021-02-10
GBGB2101824.7A GB202101824D0 (en) 2021-02-10 2021-02-10 Coronavirus vaccines
GB2103214.9 2021-03-08
GBGB2103214.9A GB202103214D0 (en) 2021-03-08 2021-03-08 Coronavirus vaccines
PCT/GB2021/050830 WO2021198706A2 (en) 2020-04-01 2021-04-01 Coronavirus vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025162640A Division JP2025184979A (ja) 2020-04-01 2025-09-29 コロナウイルスワクチン

Publications (2)

Publication Number Publication Date
JP2023522156A true JP2023522156A (ja) 2023-05-29
JP2023522156A5 JP2023522156A5 (https=) 2024-05-08

Family

ID=75426636

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022560285A Pending JP2023522156A (ja) 2020-04-01 2021-04-01 コロナウイルスワクチン
JP2025162640A Pending JP2025184979A (ja) 2020-04-01 2025-09-29 コロナウイルスワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025162640A Pending JP2025184979A (ja) 2020-04-01 2025-09-29 コロナウイルスワクチン

Country Status (7)

Country Link
US (1) US20240285751A1 (https=)
EP (1) EP4126033A2 (https=)
JP (2) JP2023522156A (https=)
CN (1) CN116113431A (https=)
AU (1) AU2021249525A1 (https=)
CA (1) CA3179038A1 (https=)
WO (1) WO2021198706A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103231A4 (en) 2020-02-14 2024-03-27 Geovax, Inc. VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2
CN113527444B (zh) * 2020-04-13 2022-12-27 中国科学院微生物研究所 与新型冠状病毒的抗体有效结合的表位
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
US20240293534A1 (en) * 2021-06-14 2024-09-05 Modernatx, Inc. Coronavirus glycosylation variant vaccines
EP4183409A1 (en) * 2021-11-17 2023-05-24 Charité - Universitätsmedizin Berlin Vaccine with improved immunogenicity against mutant coronaviruses
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
JP2026508394A (ja) 2023-03-03 2026-03-10 ディオシンバックス リミテッド コロナウイルスワクチン
EP4687969A1 (en) * 2023-04-05 2026-02-11 DIOSynVax Ltd Coronavirus vaccines inducing broad immunity against variants
WO2025083402A1 (en) * 2023-10-16 2025-04-24 Diosynvax Ltd Coronavirus vaccines

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060121580A1 (en) * 2003-07-22 2006-06-08 Crucell Binding molecules against SARS-coronavirus and uses thereof
US20080027006A1 (en) * 2004-02-12 2008-01-31 The Regents Of The University Of Colorado Compositions And Methods For Modification And Prevention Of Sars Coronavirus Infectivity
US20100150923A1 (en) * 2005-06-20 2010-06-17 Chinese Academy Of Medical Sciences, Institute Of Basic Medical Sciences Fusion proteins of recombinant sars coronavirus structural proteins, their production and uses
WO2019169120A1 (en) * 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102690336A (zh) * 2012-06-11 2012-09-26 中国科学院武汉病毒研究所 蝙蝠sars样冠状病毒刺突蛋白免疫决定区及制备方法和用途
WO2015143335A1 (en) * 2014-03-20 2015-09-24 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
CN106928326B (zh) * 2015-12-31 2019-12-24 中国科学院微生物研究所 一种基于二聚化的受体结合区亚单位的冠状病毒疫苗
US11918643B2 (en) * 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060121580A1 (en) * 2003-07-22 2006-06-08 Crucell Binding molecules against SARS-coronavirus and uses thereof
US20080027006A1 (en) * 2004-02-12 2008-01-31 The Regents Of The University Of Colorado Compositions And Methods For Modification And Prevention Of Sars Coronavirus Infectivity
US20100150923A1 (en) * 2005-06-20 2010-06-17 Chinese Academy Of Medical Sciences, Institute Of Basic Medical Sciences Fusion proteins of recombinant sars coronavirus structural proteins, their production and uses
WO2019169120A1 (en) * 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KANGPENG XIAO ET AL.: "Isolation and Characterization of 2019-nCoV-like Coronavirus from Malayan Pangolins", BIORXIV, JPN6025012642, 20 February 2020 (2020-02-20), ISSN: 0005739837 *
WANBO TAI ET AL., CELLULAR & MOLECULAR IMMUNOLOGY, vol. 17, JPN6025012643, 19 March 2020 (2020-03-19), pages 613 - 620, ISSN: 0005739838 *

Also Published As

Publication number Publication date
CN116113431A (zh) 2023-05-12
AU2021249525A1 (en) 2022-12-08
WO2021198706A3 (en) 2021-12-02
JP2025184979A (ja) 2025-12-18
CA3179038A1 (en) 2021-10-07
EP4126033A2 (en) 2023-02-08
US20240285751A1 (en) 2024-08-29
WO2021198706A2 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
JP2023522156A (ja) コロナウイルスワクチン
Xu et al. Antibodies and vaccines against Middle East respiratory syndrome coronavirus
US12311021B2 (en) Replication-competent attenuated chimeric VSV vectors encoding immunogenic SARS-CoV-2 spike proteins
WO2022218272A1 (zh) 新型冠状病毒突变株s蛋白及其亚单位疫苗
Law et al. SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1
Zhou et al. Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines
CN107029227A (zh) 热稳定的呼吸道合胞病毒融合前 f 蛋白寡聚物及其在免疫组合物中的用途
Yang et al. Immunization of mice with vaccinia virus Tiantan strain yields antibodies cross-reactive with protective antigens of monkeypox virus
US10251948B2 (en) Anti-HIV vaccine constructed based on amino acid mutations in attenuated live EIAV vaccine
US20240252617A1 (en) Coronavirus spike protein designs, compositions and methods for their use
JP2024539609A (ja) コロナウイルスワクチン
Salleh Structural biology of Nipah virus G and F glycoproteins: Insights into therapeutic and vaccine development
Wang et al. Development and identification of porcine monoclonal antibodies against PEDV from single B cells
KR101845571B1 (ko) 전통적 돼지열에 대한 마커 백신
Zakhartchouk et al. Optimization of a DNA vaccine against SARS
Tsunetsugu‐Yokota et al. Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine
US20220296701A1 (en) Synthetic plasmid dna vaccine expressing a codon-optimized sars-cov-2 spike protein and methods for its use
Xu et al. Generation and characterization of a monoclonal antibody against duck Tembusu virus envelope protein
WO2023092023A2 (en) Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19)
CN114634579A (zh) 一种抗新冠病毒基因工程疫苗
Lebedin et al. SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody
CN113227360A (zh) 具有新型流感病毒来源的血凝素蛋白基因的DIs株来源的重组牛痘病毒
Lee et al. Coronavirus nucleocapsid-based vaccine provides partial protection against hetero-species coronavirus in murine models
Lee et al. Mosaic receptor-binding domain nanoparticles induce protective immunity against SARS-CoV-2 challenges
EP3628678A1 (en) Immunogen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250929

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251126